跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 5,692 条关于
“Kailera Bio”
全部
5,692
临床试验
2,533
药物
1,027
机构
277
资讯
1,855
去年
Kailera Bio Obtains $400M to Fast-Track Obesity Drug into Phase 3 Trials
去年
Kailera Therapeutics Launches with $400M to Advance GLP-1 Based Obesity Therapies
11个月前
Kailera Therapeutics Secures $600M Series B to Advance Obesity Drug KAI-9531 to Phase 3 Trials
9个月前
GLP-1 Pricing Agreements Open Market for New Obesity Drug Competitors
去年
Hengrui and Kailera's Dual GLP-1/GIP Obesity Drug Achieves 18% Weight Loss in Phase 3 Trial
去年
Kailera's HRS9531 Shows Strong Phase II Weight Loss, Pfizer Cautious on Danuglipron
去年
Kailera Therapeutics Strengthens Commercial Leadership with Ex-Lilly Executive Jamie Coleman Ahead of Phase 3 Obesity Drug Program
4个月前
Kailera and Hengrui Present Promising Ribupatide Data at ADA 2026, Demonstrating Strong Weight Loss Efficacy
8个月前
Kailera Therapeutics Initiates Global Phase 3 Trials for Dual GLP-1/GIP Obesity Drug Following Strong Chinese Study Results
去年
Hengrui and Kailera Present Phase 2 Data for Dual GLP-1/GIP Agonist and Oral GLP-1 Therapies at ADA 2025
第 1 页,共 186 页
上一页
下一页